首页 > 最新文献

The Lancet Oncology最新文献

英文 中文
Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK 英国癌症疫苗临床试验的现状、成功和主要挑战
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00723-5
Robert A Watson, Darcy Ward, Pippa Corrie, Elisa Fontana, William Ince, Victoria Kunene, Siow-Ming Lee, Mark Linch, Nangi Lo, Christian Ottensmeier, Miranda Payne, David Pinato, Thomas Powles, Elizabeth Smyth, Stefan N Symeonides, Fiona Thistlethwaite, Ojas Rajkumar, Henry Li, Lennard Lee
{"title":"Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK","authors":"Robert A Watson, Darcy Ward, Pippa Corrie, Elisa Fontana, William Ince, Victoria Kunene, Siow-Ming Lee, Mark Linch, Nangi Lo, Christian Ottensmeier, Miranda Payne, David Pinato, Thomas Powles, Elizabeth Smyth, Stefan N Symeonides, Fiona Thistlethwaite, Ojas Rajkumar, Henry Li, Lennard Lee","doi":"10.1016/s1470-2045(25)00723-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00723-5","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145813996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer consequences of the HIV funding crisis 艾滋病资金危机对癌症的影响
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00722-3
The Lancet Oncology
{"title":"Cancer consequences of the HIV funding crisis","authors":"The Lancet Oncology","doi":"10.1016/s1470-2045(25)00722-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00722-3","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145813999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Micrometastatic axillary disease after neoadjuvant treatment 新辅助治疗后的微转移性腋窝疾病
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00647-3
Tove Filtenborg Tvedskov
{"title":"Micrometastatic axillary disease after neoadjuvant treatment","authors":"Tove Filtenborg Tvedskov","doi":"10.1016/s1470-2045(25)00647-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00647-3","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 替莫唑胺并发和辅助治疗1p/19q非共缺失间变性胶质瘤(CATNON; EORTC研究26053-22054):一项随机、开放标签、3期试验的最终探索性分析
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00614-x
Prof Martin J van den Bent MD, Santoesha A Ghisai MSc, Prof Wolfgang Wick MD, Prof Marc Sanson MD, Alba Ariela Brandes MD, Prof Paul M Clement MD, Sara C Erridge MD, Prof Michael A Vogelbaum MD, Prof Anna K Nowak MD, Prof Jean-François Baurain MD, Prof Warren P Mason MD, Helen Wheeler MD, Prof Emeline Tabouret MD, Sanjeev Gill MD, Matthew Griffin MD, Walter Taal MD, Prof Roberta Rudà MD, Prof Michael Weller MD, Catherine McBain MD, Jaap C Reijneveld MD, Roelien H Enting MD, Sébastien Tran MD, Thierry Lesimple MD, Martin Kocher MD, Anja Gijtenbeek MD, Elizabeth Lim MD, Prof Ulrich Herrlinger MD, Prof Peter Hau MD, Frederic Dhermain MD, Kenneth Aldape MD, Prof Robert B Jenkins MD, Hendrikus Jan Dubbink PhD, Prof Johan M Kros MD, Prof Pieter Wesseling MD, Youri Hoogstrate PhD, Sarah Nuyens, Vassilis Golfinopoulos MD, C Mircea S Tesileanu MD, Thierry Gorlia PhD, Prof Pim French PhD, Brigitta G Baumert MD
The CATNON trial investigated the benefit of the addition of concurrent or adjuvant temozolomide to radiotherapy in individuals with anaplastic astrocytoma. We report the long-term follow-up of the study focusing on the individuals with isocitrate dehydrogenase (IDH) mutated (IDHmt) tumours.
CATNON试验研究了间变性星形细胞瘤患者放射治疗中同时或辅助使用替莫唑胺的益处。我们报告了对异柠檬酸脱氢酶(IDH)突变(IDHmt)肿瘤患者的长期随访研究。
{"title":"Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial","authors":"Prof Martin J van den Bent MD, Santoesha A Ghisai MSc, Prof Wolfgang Wick MD, Prof Marc Sanson MD, Alba Ariela Brandes MD, Prof Paul M Clement MD, Sara C Erridge MD, Prof Michael A Vogelbaum MD, Prof Anna K Nowak MD, Prof Jean-François Baurain MD, Prof Warren P Mason MD, Helen Wheeler MD, Prof Emeline Tabouret MD, Sanjeev Gill MD, Matthew Griffin MD, Walter Taal MD, Prof Roberta Rudà MD, Prof Michael Weller MD, Catherine McBain MD, Jaap C Reijneveld MD, Roelien H Enting MD, Sébastien Tran MD, Thierry Lesimple MD, Martin Kocher MD, Anja Gijtenbeek MD, Elizabeth Lim MD, Prof Ulrich Herrlinger MD, Prof Peter Hau MD, Frederic Dhermain MD, Kenneth Aldape MD, Prof Robert B Jenkins MD, Hendrikus Jan Dubbink PhD, Prof Johan M Kros MD, Prof Pieter Wesseling MD, Youri Hoogstrate PhD, Sarah Nuyens, Vassilis Golfinopoulos MD, C Mircea S Tesileanu MD, Thierry Gorlia PhD, Prof Pim French PhD, Brigitta G Baumert MD","doi":"10.1016/s1470-2045(25)00614-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00614-x","url":null,"abstract":"The CATNON trial investigated the benefit of the addition of concurrent or adjuvant temozolomide to radiotherapy in individuals with anaplastic astrocytoma. We report the long-term follow-up of the study focusing on the individuals with isocitrate dehydrogenase (<ce:italic>IDH</ce:italic>) mutated (<ce:italic>IDHmt</ce:italic>) tumours.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer 可切除和交界性可切除胰腺癌的preopac -2试验
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00601-1
John P Neoptolemos, Christoph Springfeld, Daniel Öhlund, Markus W Büchler, Christoph W Michalski
{"title":"The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer","authors":"John P Neoptolemos, Christoph Springfeld, Daniel Öhlund, Markus W Büchler, Christoph W Michalski","doi":"10.1016/s1470-2045(25)00601-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00601-1","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making 由PIONEER联盟和RANO切除组提供的胶质瘤手术的综合框架,第1部分:术中绘图、监测和决策的建议
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00531-5
Jasper K W Gerritsen MD PhD, Philipp Karschnia MD MSc, Prof Lorenzo Bello MD PhD, Prof Shawn Hervey-Jumper MD, Jacob S Young MD, Prof Kathleen Seidel MD, Djaina D Satoer PhD, Prof Oliver Schnell MD MHBA, Michael Parsons PhD, Brian V Nahed MD FACS, Grazia Menna MD, Nico Teske MD MSc, External Rater Panel, Keyoumars Ashkan, Marion Barberis, Chetan Bettegowda, Florien Boele, Richard W. Byrne, Daniel P. Cahill, Daniel Delev, Elke De Witte, Katharine Drummond, Johnny Duerinck, Gavin Dunn, Samuel Emerson, Yoshua Esquenazi, Christian F. Freyschlag, Marjolein Geurts, Rachel Grossman, Constantinos G. Hadjipanayis, Margret Jensdottir, Markus Klimek, Chanhung Lee, Amy Maguire, Alireza Mansouri, James M. Markert, Yoshitaka Narita, Alessandro Olivi, Johan Pallud, Karin Piil, Matthias Preusser, Alfredo Quinones-Hinojosa, Jane Skjøth-Rasmussen, Michael Sabel, Christian Senft, Susan Short, Ole S. Solheim, Walter Stummer, Andrea Szelényi, Einar O. Vik-Mo, Colin Watts, Michael Weller, Patrick Wen, Timothy R Smith MD PhD, Nader Sanai MD, Prof Sandro M Krieg MD MBA, Prof Philippe Schucht MD, Prof Marike L D Broekman MD PhD, Prof Steven De Vleeschouwer MD PhD, Prof Asgeir S Jakola MD PhD, Prof Martin J van den Bent MD PhD, Prof Susan M Chang MD, Michael A Vogelbaum MD PhD, Prof Arnaud J P E Vincent MD PhD, Prof Joerg-Christian Tonn MD, Prof Mitchel S Berger MD FACS
In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional tests to be used intraoperatively, or intraoperative decision making. Furthermore, there are no consensus standardised neurological, language, and functional outcome assessments that should be applied pre-operatively and post-operatively. The Personalized Interventions and Outcomes in Neurosurgical Oncology Research (PIONEER) Consortium and the Response Assessment in Neuro-Oncology (RANO) resect group are collaborative, multidisciplinary efforts that aim to standardise and enhance research and clinical practices in surgical neuro-oncology. Here, both working groups review the evidence and provide recommendations in an effort to improve standardisation in intraoperative stimulation mapping, electrophysiological monitoring, and intraoperative decision making during glioma resections in adults. The Policy Review offers an intraoperative framework to reduce heterogeneity and improve the quality of clinical and scientific practice. In addition to standardising practices and improving individual patient outcomes, this Policy Review provides a foundation for better consistency between institutions and facilitates multicentre collaboration in surgical neuro-oncology. Ultimately, reducing heterogeneity might accelerate the development of personalised surgical care by enabling advanced computational modelling techniques.
在新诊断或复发的成年弥漫性胶质瘤患者中,更广泛的切除与更长的无进展和总生存期相关。术中作图技术通过定位、监测和保留手术中潜在浸润脑的功能来安全地增加切除范围。然而,对于术中定位的适应症、术中使用的最佳功能测试或术中决策尚无共识。此外,对于术前和术后的神经学、语言和功能预后评估,目前还没有统一的标准。神经外科肿瘤研究的个性化干预和结果(PIONEER)联盟和神经肿瘤的反应评估(RANO)切除组是合作的,多学科的努力,旨在标准化和加强外科神经肿瘤的研究和临床实践。在此,两个工作小组回顾了证据并提出了建议,以努力提高成人胶质瘤切除术中术中刺激制图、电生理监测和术中决策的标准化。政策审查提供了一个术中框架,以减少异质性,提高临床和科学实践的质量。除了标准化实践和改善个体患者的治疗结果外,该政策审查还为机构之间更好的一致性提供了基础,并促进了外科神经肿瘤学的多中心合作。最终,通过实现先进的计算建模技术,减少异质性可能会加速个性化手术护理的发展。
{"title":"A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making","authors":"Jasper K W Gerritsen MD PhD, Philipp Karschnia MD MSc, Prof Lorenzo Bello MD PhD, Prof Shawn Hervey-Jumper MD, Jacob S Young MD, Prof Kathleen Seidel MD, Djaina D Satoer PhD, Prof Oliver Schnell MD MHBA, Michael Parsons PhD, Brian V Nahed MD FACS, Grazia Menna MD, Nico Teske MD MSc, External Rater Panel, Keyoumars Ashkan, Marion Barberis, Chetan Bettegowda, Florien Boele, Richard W. Byrne, Daniel P. Cahill, Daniel Delev, Elke De Witte, Katharine Drummond, Johnny Duerinck, Gavin Dunn, Samuel Emerson, Yoshua Esquenazi, Christian F. Freyschlag, Marjolein Geurts, Rachel Grossman, Constantinos G. Hadjipanayis, Margret Jensdottir, Markus Klimek, Chanhung Lee, Amy Maguire, Alireza Mansouri, James M. Markert, Yoshitaka Narita, Alessandro Olivi, Johan Pallud, Karin Piil, Matthias Preusser, Alfredo Quinones-Hinojosa, Jane Skjøth-Rasmussen, Michael Sabel, Christian Senft, Susan Short, Ole S. Solheim, Walter Stummer, Andrea Szelényi, Einar O. Vik-Mo, Colin Watts, Michael Weller, Patrick Wen, Timothy R Smith MD PhD, Nader Sanai MD, Prof Sandro M Krieg MD MBA, Prof Philippe Schucht MD, Prof Marike L D Broekman MD PhD, Prof Steven De Vleeschouwer MD PhD, Prof Asgeir S Jakola MD PhD, Prof Martin J van den Bent MD PhD, Prof Susan M Chang MD, Michael A Vogelbaum MD PhD, Prof Arnaud J P E Vincent MD PhD, Prof Joerg-Christian Tonn MD, Prof Mitchel S Berger MD FACS","doi":"10.1016/s1470-2045(25)00531-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00531-5","url":null,"abstract":"In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional tests to be used intraoperatively, or intraoperative decision making. Furthermore, there are no consensus standardised neurological, language, and functional outcome assessments that should be applied pre-operatively and post-operatively. The Personalized Interventions and Outcomes in Neurosurgical Oncology Research (PIONEER) Consortium and the Response Assessment in Neuro-Oncology (RANO) resect group are collaborative, multidisciplinary efforts that aim to standardise and enhance research and clinical practices in surgical neuro-oncology. Here, both working groups review the evidence and provide recommendations in an effort to improve standardisation in intraoperative stimulation mapping, electrophysiological monitoring, and intraoperative decision making during glioma resections in adults. The Policy Review offers an intraoperative framework to reduce heterogeneity and improve the quality of clinical and scientific practice. In addition to standardising practices and improving individual patient outcomes, this Policy Review provides a foundation for better consistency between institutions and facilitates multicentre collaboration in surgical neuro-oncology. Ultimately, reducing heterogeneity might accelerate the development of personalised surgical care by enabling advanced computational modelling techniques.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"107 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula 模拟动静脉瘘的滑膜肉瘤引起的高输出量心力衰竭
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00664-3
Yuxi Chen MD, Jingwei Zhou MD, Hongyuan Liu MD, Xiaoxi Lin MD, Chen Hua MD
{"title":"High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula","authors":"Yuxi Chen MD, Jingwei Zhou MD, Hongyuan Liu MD, Xiaoxi Lin MD, Chen Hua MD","doi":"10.1016/s1470-2045(25)00664-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00664-3","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply preopac -2在可切除和边缘性可切除胰腺癌中的临床试验——作者的答复
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00729-6
Quisette P Janssen, Jacob L van Dam, Marc G Besselink, Johanna W Wilmink, Marjolein Y V Homs, Geertjan van Tienhoven, Casper H J van Eijck, Bas Groot Koerkamp
{"title":"The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply","authors":"Quisette P Janssen, Jacob L van Dam, Marc G Besselink, Johanna W Wilmink, Marjolein Y V Homs, Geertjan van Tienhoven, Casper H J van Eijck, Bas Groot Koerkamp","doi":"10.1016/s1470-2045(25)00729-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00729-6","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145813993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 纳武单抗加多西他赛与安慰剂加多西他赛治疗雄激素受体途径抑制剂预处理和化疗初始转移性阉割抵抗性前列腺癌(CheckMate 7DX):一项双盲、随机、3期试验
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00566-2
Prof Karim Fizazi MD, Prof Fred Saad MD, Teresa Alonso-Gordoa MD PhD, Bogdan Żurawski MD, Philippe Barthélémy MD PhD, Eric Voog MD, Hernán Javier Cutuli MD, Prof Tomas Buchler MD, Prof Dingwei Ye MD, Daniel Castellano MD, Mariusz Kwiatkowski MD, Prof Cagatay Arslan MD, Prof Martin Richardet MD, Constantine Alifrangis MD, Jeffrey C Goh MBBS, Karina Vianna MD, Prof Weiqing Han MD, Koji Hatano MD, Tilmann Todenhöfer MD, Prof Margitta Retz MD, Abhinav Srivastava MPhil, Chelsea Jin MD, Saurabh Gupta PhD, Gilda Trandafirescu MD, Arancha Campos MPharm, Chung-Wei Lee MD, Maximiliano van Kooten Losio MD, Sumit K Subudhi MD PhD
Androgen receptor pathway inhibitors (ARPIs) and docetaxel are established standards of care for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). We aimed to assess the efficacy and safety of adding nivolumab to docetaxel versus docetaxel alone in ARPI-pretreated, chemotherapy-naive mCRPC.
雄激素受体途径抑制剂(arpi)和多西紫杉醇是化疗初期转移性去势抵抗性前列腺癌(mCRPC)的既定护理标准。我们的目的是评估在arpi预处理的化疗初始mCRPC中,将纳武单抗加入多西他赛与单独多西他赛的疗效和安全性。
{"title":"Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial","authors":"Prof Karim Fizazi MD, Prof Fred Saad MD, Teresa Alonso-Gordoa MD PhD, Bogdan Żurawski MD, Philippe Barthélémy MD PhD, Eric Voog MD, Hernán Javier Cutuli MD, Prof Tomas Buchler MD, Prof Dingwei Ye MD, Daniel Castellano MD, Mariusz Kwiatkowski MD, Prof Cagatay Arslan MD, Prof Martin Richardet MD, Constantine Alifrangis MD, Jeffrey C Goh MBBS, Karina Vianna MD, Prof Weiqing Han MD, Koji Hatano MD, Tilmann Todenhöfer MD, Prof Margitta Retz MD, Abhinav Srivastava MPhil, Chelsea Jin MD, Saurabh Gupta PhD, Gilda Trandafirescu MD, Arancha Campos MPharm, Chung-Wei Lee MD, Maximiliano van Kooten Losio MD, Sumit K Subudhi MD PhD","doi":"10.1016/s1470-2045(25)00566-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00566-2","url":null,"abstract":"Androgen receptor pathway inhibitors (ARPIs) and docetaxel are established standards of care for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). We aimed to assess the efficacy and safety of adding nivolumab to docetaxel versus docetaxel alone in ARPI-pretreated, chemotherapy-naive mCRPC.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial 基于分子谱的高中危子宫内膜癌女性辅助治疗(PORTEC-4a):一项随机、开放标签、多中心、非劣性试验的结果
Pub Date : 2025-12-22 DOI: 10.1016/s1470-2045(25)00612-6
Anne Sophie V M van den Heerik MD, Nanda Horeweg MD PhD, Marie A D Haverkort MD, Nienke Kuijsters MD PhD, Prof Stefan Kommoss MD, Friederike L A Koppe MD, Marlies E Nowee MD PhD, Henrike Westerveld MD PhD, Maria A A De Jong MD, Filip Frühauf MD PhD, Jeltsje S Cnossen MD PhD, Jan Willem M Mens MD, Jannet C Beukema MD PhD, Prof Cyrus Chargari MD PhD, Charles Gillham MD, Ina M Jurgenliemk-Schulz MD PhD, Prof Katrien Vandecasteele MD PhD, Moritz Hamann MD, Mandy Kiderlen MD PhD, Prof Annette Staebler MD PhD, Prof Hans W Nijman MD PhD, Bastiaan G Wortman MD PhD, Elefteria Asteinidou PhD, Stephanie M de Boer MD PhD, Wilbert B van den Hout PhD, Karen W Verhoeven-Adema PhD, Prof Remi A Nout MD PhD, Prof Hein Putter PhD, Prof Tjalling Bosse MD PhD, Prof Carien L Creutzberg MD PhD
PORTEC-4a investigated molecular risk profile-based individualised adjuvant treatment for women with high-intermediate risk endometrial cancer, aiming to reduce both overtreatment and undertreatment while optimising locoregional control.
PORTEC-4a研究了基于分子风险谱的中高危子宫内膜癌女性个体化辅助治疗,旨在减少过度治疗和治疗不足,同时优化局部区域控制。
{"title":"Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial","authors":"Anne Sophie V M van den Heerik MD, Nanda Horeweg MD PhD, Marie A D Haverkort MD, Nienke Kuijsters MD PhD, Prof Stefan Kommoss MD, Friederike L A Koppe MD, Marlies E Nowee MD PhD, Henrike Westerveld MD PhD, Maria A A De Jong MD, Filip Frühauf MD PhD, Jeltsje S Cnossen MD PhD, Jan Willem M Mens MD, Jannet C Beukema MD PhD, Prof Cyrus Chargari MD PhD, Charles Gillham MD, Ina M Jurgenliemk-Schulz MD PhD, Prof Katrien Vandecasteele MD PhD, Moritz Hamann MD, Mandy Kiderlen MD PhD, Prof Annette Staebler MD PhD, Prof Hans W Nijman MD PhD, Bastiaan G Wortman MD PhD, Elefteria Asteinidou PhD, Stephanie M de Boer MD PhD, Wilbert B van den Hout PhD, Karen W Verhoeven-Adema PhD, Prof Remi A Nout MD PhD, Prof Hein Putter PhD, Prof Tjalling Bosse MD PhD, Prof Carien L Creutzberg MD PhD","doi":"10.1016/s1470-2045(25)00612-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00612-6","url":null,"abstract":"PORTEC-4a investigated molecular risk profile-based individualised adjuvant treatment for women with high-intermediate risk endometrial cancer, aiming to reduce both overtreatment and undertreatment while optimising locoregional control.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The Lancet Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1